

1 **Comparison of NAFLD, MAFLD, MASLD and pure-MASLD characteristics and mortality**
2 **outcomes in United States adults**

3

4 Running title: Comparison of NAFLD, MAFLD, MASLD and pure-MASLD

5

6 Rui Song^{1#}, Zhao Li^{2#}, Yingzhi Zhang^{1#}, Jiahe Tan³, Zhiwei Chen^{1*}

7

8 ¹ Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute
9 for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital of
10 Chongqing Medical University, Chongqing, China

11 ² Department of Gastroenterology, the Seventh People's Hospital of Chongqing, Chongqing,
12 China.

13 ³ Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University,
14 Chongqing, China.

15

16 # These authors contribute equally to this work.

17 * Corresponding author. Address: Institute for Viral Hepatitis, The Key Laboratory of Molecular
18 Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of
19 Chongqing Medical University, 74 Linjiang Road, Yuzhong District, Chongqing 400010, China.

20 E-mail addresses: zhiwei_chen@cqmu.edu.cn.

21

22 Key words: NAFLD; MAFLD; MASLD; pure-MASLD; mortality; NHANES III

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 **Background:** After metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic
25 fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-
26 associated steatotic liver disease (MASLD). However, the distinctions in characteristics and
27 mortality outcomes between NAFLD, MAFLD, MASLD, and pure-MASLD are still unclear.

28 **Methods:** We analyzed data from 6,708 participants in the third National Health and Nutrition
29 Examination Surveys 1988-1994 of United States (US) and their linked mortality through 2019.
30 NAFLD, MAFLD, MASLD and pure MASLD were defined based on respective criteria. Survey-
31 weight adjusted multivariable Cox proportional model was used to study the mortality of the four
32 terms.

33 **Results:** The overall prevalence of NAFLD, MAFLD, MASLD and pure-MASLD was 28.9%
34 (n=1,937), 26.1% (n=1,753), 29.0% (n=1,948), and 26.0% (n=1,741), respectively. For NAFLD,
35 81.3%, 89.9% and 89.9% fulfilled the criteria for MAFLD, MASLD and pure MASLD. For
36 MAFLD, all were classified into the MASLD, and 89.8% were met the criteria of pure-MASLD.
37 During a median follow-up of 27 years, both individuals with MAFLD and MASLD had higher
38 risk of all-cause mortality (adjusted hazard ratio [aHR]: 1.21, 95% CI 1.09-1.352; and 1.11, 1.00-
39 1.23, respectively). NAFLD and pure-MASLD were not associated with all-cause mortality. All
40 the four terms were associated with increased all-cause mortality in individuals with advanced
41 fibrosis (aHR: 1.66-1.83). Subgroup analyses showed that higher risk of all-cause mortality of
42 NAFLD, MAFLD, MASLD and pure-MASLD were observed in female, age 41-55 years, non-
43 Hispanic white, and never smoking subgroups when focused on moderate-severe hepatic steatosis.

44 **Conclusions:** In this US population-based study, MASLD could identify more individuals with

45 all-cause mortality risk than MAFLD, meanwhile, NAFLD and pure-MASLD had similar

46 characteristics and mortality outcomes.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67 **Introduction**

68 Non-alcoholic fatty liver disease (NAFLD) has become one of the leading causes of chronic liver
69 disease in the world, which can progress into hepatic fibrosis and end-stage liver diseases
70 eventually ¹. Most recently, a new term metabolic dysfunction-associated steatotic liver disease
71 (MASLD) was recommended to replace NAFLD and metabolic dysfunction-associated fatty liver
72 disease (MAFLD) by the Delphi consensus ², which involved a change in not only the
73 nomenclature but also the definition. MASLD, as the umbrella term, comprised broader metabolic
74 risk factors, and can co-exist with other chronic liver diseases. To better distinguish the etiologies,
75 MASLD was further classed into pure-MASLD, MetALD or MASLD with other combination
76 etiology ². Since the new term of MASLD was proposed, it is concern whether the new definition
77 of MASLD will impact the old NAFLD data using, biomarker discovery or the nature history.
78 Moreover, some are worried that this new term will add the difficulty and confusion to people due
79 to frequent changes in nomenclature of NAFLD ^{3 4}. Hence, it is urgent for us to clarify the relation
80 characteristic and mortality outcomes of these terms in clinical practice.

81 Several studies found that NAFLD was highly in accordance with MASLD in clinical features ⁵⁻⁸,
82 however, these studies were limited by the use of small or specific patient populations. A recent
83 study reported similar prevalence and risk factors of NAFLD, MAFLD and MASLD in a large
84 Brazilian cohort, but the long-term mortalities among these terms are not assessed ⁹. Some studies
85 evaluated the mortality outcomes of MASLD and/or MAFLD, but showed inconsistent results ¹⁰⁻
86 ¹². Meanwhile, the comparison of NAFLD, MAFLD, MASLD and pure-MASLD clinical
87 outcomes was not performed in these previous studies. Therefore, the similarities and differences
88 of characteristic and long-term mortality among individuals with NAFLD, MAFLD, MASLD and

89 pure-MASLD in a general population are still unknown.

90 In this study, we conducted a comprehensive analysis in 6708 nonpregnant adult participants from
91 the Third National Health and Nutrition Examination Survey 1988-1994 (NHANES III). By using
92 the nationally representative sample of United States (US) adults, we compared the relationship
93 and clinical features among NAFLD, MAFLD, MASLD and pure-MASLD, and assessed the
94 association of the four terms on all-cause and cause-specific mortality.

95

96 **Materials and methods**

97 **Study design and participants**

98 The NHANES III is a national survey program to assess health and nutritional status obtained
99 using a complex, stratified, clustered multi-staged probability sampling design to acquire a
100 nationally representative sample of US populations¹³. This survey included demographic data,
101 health-related questionnaires, physical examinations, laboratory tests, and hepatic/gallbladder
102 ultrasound in 13,588 nonpregnant adults (20-74 years).
103 First, we excluded 1,261 individuals with missing data on mortality status, body mass index, waist
104 circumference, and laboratory tests, including high-density lipoprotein (HDL)-cholesterol,
105 triglycerides, hemoglobin A1c and fasting glucose. Because of focusing on hepatic steatosis in this
106 study, not steatohepatitis, we then excluded 1,223 individuals with elevated liver enzymes levels.
107 To accurately assess the effect of alcohol intake on SLD, we further excluded 4,228 individuals
108 with missing data on alcohol assumption. In addition, we also excluded 258 individuals with HCV
109 and/or HBV infection, and those with a BMI <18.5 kg/m², given the potential confounding effect
110 of viral hepatitis and undernutrition. Lastly, 6,708 individuals were included for the main analysis

111 in this study (Figure. S1). There is no significant difference of demographic and clinical
112 characteristics among populations during selection process (Table S1). All individuals signed
113 informed consent to participate in NHANES III.

114 **Data collection**

115 For each participant of NHANES III, the information about demographic indexes (such as sex,
116 age, ethnicity, education, marital status, smoking, alcohol consumption, physical activity,
117 underlying diseases, and drug use), anthropometric indexes (such as body mass index (BMI),
118 waist circumference, and blood pressure), and laboratory tests (such as alanine aminotransferase,
119 aspartate aminotransferase, HDL-cholesterol, fasting glucose) were collected. The definitions,
120 such as hypertension, diabetes, smoking status, alcohol consumption, sedentary behavior, were
121 provided in the supplementary materials.

122 **Definition of NAFLD, MAFLD, MASLD, pure-MASLD and advanced fibrosis**

123 In NHANES III, the ultrasonographic assessments were reported as normal vs. mild, moderate, or
124 severe hepatic steatosis ¹⁴. We defined steatosis liver diseases (SLD) as mild to severe hepatic
125 steatosis without increased liver enzymes levels in this study. NAFLD was defined as the presence
126 of SLD without excessive alcohol consumption (≥ 20 g/d for females and ≥ 30 g/d for males)
127 and/or other liver diseases (such as viral hepatitis) ¹⁵. MAFLD was defined as the presence of SLD
128 with metabolic dysfunction, which comprises either overweight or obese (BMI ≥ 25 kg/m²),
129 diabetes mellitus, or a combination of at least 2 of the 7 metabolic risk abnormalities ¹⁶. MASLD
130 was defined as the presence of SLD combined with at least 1 of the 5 cardiometabolic adult
131 criteria ². Pure-MASLD was defined as the presence of MASLD without excessive alcohol
132 consumption and other combination etiologies ². MetALD was defined as the presence of MASLD

133 with higher alcohol consumption levels (20 to 50 g/d for females and 30 to 60 g/d for males) ².
134 This detail definitions of MAFLD and MASLD were showed in the supplementary materials.
135 To give an insight into the similarities and differences between the four terms, individuals were
136 further classified into different groups. For example, we defined NAFLD+ as individuals who met
137 the definition of NAFLD, and NAFLD- was defined as individuals who didn't meet NAFLD
138 definition. Likewise, NAFLD+/MAFLD-/MASLD-/pure-MASLD+ means an individual who met
139 both NAFLD and pure-MASLD definitions but not the definitions of MAFLD and MASLD.
140 Individuals without hepatic steatosis were referred to as a group with no hepatic steatosis.
141 We using the NAFLD fibrosis score (NFS) to evaluate advanced fibrosis of individual with SLD
142 ¹⁷. In detail, high (NFS >0.676), intermediate (NFS 0.676 to -1.455) and low probability for
143 advanced fibrosis (NFS <-1.455) were defined.

144 **All-cause and cause-specific mortality**

145 The mortality data of adults in the NHANES III was passively follow-up and obtained from the
146 National Death Index, which contained complete data until December 31, 2019 ¹⁸. The definition
147 of all-cause mortality and cause-specific (cardiovascular disease and cancer) mortalities were
148 showed in a previous study ¹⁹, and detailed information was presented in the supplementary
149 materials. Moreover, we calculated the follow-up time (month) from the date of interview to the
150 date of death or the end of the follow-up period.

151 **Statistical analysis**

152 The results of the baseline characteristics are expressed as median and interquartile range (IQR)
153 for continuous variables and unweighted frequency counts and weighted percentage for
154 categorical variables. We compared baseline characteristics using the Kruskal-Wallis test for

155 continuous variables and the chi-square test for categorical variables. Cox proportional hazards
156 regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for deaths
157 from all-causes, cardiovascular disease and cancer. To avoid an overadjustment bias in the
158 multivariable analysis ²⁰, we discarded the related variables which have presented in the definition
159 of NAFLD, MAFLD and MASLD. We used two models with progressive degrees of adjustment:
160 model 1 adjusted for age, sex, and ethnicity; model 2 further adjusted for education, marital status,
161 smoking status, and sedentary lifestyle.

162 For sensitivity analysis, first, we added participants with hepatitis B, hepatitis C, or BMI < 18.5
163 kg/m² into the entire population. Second, to assess the effect of varying degrees of SLD, we
164 carried out another sensitivity analysis comparing the group with no hepatic steatosis against those
165 with moderate- severe hepatic steatosis (that is, excluding those with mild steatosis from
166 individuals with SLD).

167 Lastly, we evaluated the association of NAFLD, MAFLD, MASLD and pure-MASLD with all-
168 cause mortality for subgroups defined by age, sex, ethnicity, BMI, diabetes, hypertension, and
169 smoking status. All analyses were performed with R (version 4.3.0; R Foundation for Statistical
170 Computing, Vienna, Austria), using the survey package to account for the sampling weights and
171 the complex survey design in the NHANES III.

172

173 **Results**

174 **Characteristics of NAFLD, MAFLD, MASLD and pure-MASLD**

175 After included individuals with available alcohol consumption and liver ultrasound data and
176 excluded individuals with increased liver enzymes levels or viral hepatitis etc., a total of 6708

177 participants from NHANES III were eligible for the final analysis (Figure. S1). The overall
178 prevalence of SLD, NAFLD, MAFLD, MASLD and pure-MASLD was 32.3% (n=2,164), 28.9%
179 (n=1,937), 26.1% (n=1,753), 29.0% (n=1948), and 26.0% (n=1,741), respectively (Figure 1).
180 Compared no hepatic steatosis group, older, less educated, obese, sedentary, and more coexisting
181 metabolic risk factors were observed in SLD group. Among NAFLD, MAFLD, MASLD and pure-
182 MASLD groups, individuals with MAFLD were more likely to be older, male, higher BMI and
183 waist circumference, higher alcohol intake, hypertension, and diabetes. (Table S2)
184 Further classified into different combinations of the 2,164 SLD individuals, six groups were
185 generated (NAFLD+/MAFLD+/MASLD+/pure-MASLD+, NAFLD+/MAFLD-/MASLD+/pure-
186 MASLD+, NAFLD-/MAFLD+/MASLD+/pure-MASLD-, NAFLD+/MAFLD-/MASLD-/pure-
187 MASLD-, NAFLD-/MAFLD-/MASLD+/pure-MASLD-, and NAFLD-/MAFLD-/MASLD-/pure-
188 MASLD-; Figure 1). As shown in Figure 1, most individuals with SLD were classified into
189 NAFLD+/MAFLD+/MASLD+/pure-MASLD+ (72.8%), followed by NAFLD+/MAFLD-
190 /MASLD-/pure-MASLD- (9.1%), NAFLD-/MAFLD+/MASLD+/pure-MASLD- (8.2%),
191 NAFLD+/MAFLD-/MASLD+/pure-MASLD+ (7.7%), NAFLD-/MAFLD-/MASLD+/pure-
192 MASLD- (1.3%), and NAFLD-/MAFLD-/MASLD-/pure-MASLD- (0.9%). For individuals with
193 NAFLD, 89.9% individuals were in accordance with MASLD and pure-MASLD, and 81.3%
194 individuals were in accordance with MAFLD. For individuals with MAFLD, 89.8% individuals
195 were in accordance with NAFLD and pure-MASLD, and 100% individuals in accordance with
196 MASLD. For individuals with MASLD, 89.4% individuals were in accordance with NAFLD and
197 pure-MASLD, and 90.0% individuals were in accordance with MAFLD. For individuals with
198 pure-MASLD, 100% individuals were in accordance with NAFLD and MASLD, and 90.5%

199 individuals were in accordance with MAFLD. The baseline characteristics of different
200 combinations of SLD individuals were presented in Table 1. Similarly, older, obese, hypertension,
201 diabetes, and more metabolic risk factors were more presented in individuals with MAFLD+. In
202 addition, men, and higher alcohol intake were more observed in individuals with NAFLD-.
203 Individuals with NAFLD+MAFLD- were more likely to be younger, female, lower BMI and waist
204 circumference, and lower metabolic risk factors.

205 **All-cause and cause-specific mortality of NAFLD, MAFLD, MASLD and pure-MASLD**

206 During the median follow-up of 27.0 (interquartile range: 24.6-28.9) years, the cumulative
207 mortality from all causes was 30.7% (2,061 deaths). For cause-specific mortality, cardiovascular
208 disease was 537 deaths (8.0%), and cancer was 523 deaths (7.8%). In total, individuals with SLD
209 had a 1.12-fold higher all-cause mortality than those without SLD after adjustment for
210 sociodemographic characteristics and lifestyle risk factors (model 2: adjusted HR (aHR): 1.12,
211 95% CI 1.00-1.25, Table 2). In detail, individuals with MAFLD showed a higher all-cause
212 mortality than those without MAFLD in multivariable model 2 (aHR: 1.21, 95% CI 1.09-1.35).
213 Similar result was also observed in MASLD individuals (aHR: 1.11, 95% CI 1.00-1.23). But the
214 increased risks of all-cause mortality were not presented in individuals with NAFLD or pure-
215 MASLD (aHR: 1.07, 95% CI 0.95-1.20; aHR: 1.07, 95% CI 0.96-1.19, respectively). (Table 2)
216 After stratified by etiology of MASLD, we found that only MASLD with ALD (>50 g/d for
217 females and >60 g/d for males) was associated with increased all-cause mortality compared with
218 individuals with no hepatic steatosis (aHR: 2.10, 95% CI 1.22-3.60). Individuals with MetALD
219 were not associated with all-cause mortality (aHR:1.17, 95% CI 0.84-1.64). (Table S3)
220 To further clarify the all-cause mortality among NAFLD, MAFLD, MASLD and pure-MASLD,

221 we classified SLD individuals into six groups as mentioned above. As shown in Table 2,
222 individuals with NAFLD-/MAFLD+/MASLD+/pure-MASLD- had the highest risk of all-cause
223 mortality in multivariable model 2 (aHR: 1.34, 95% CI 1.02-1.77), followed by those with
224 NAFLD+/MAFLD+/MASLD+/pure-MASLD+ (aHR: 1.17, 95% CI 1.05-1.30). Unexpectedly,
225 individuals with NAFLD+/MAFLD-/MASLD+/pure-MASLD+ showed a lower risk of all-cause
226 mortality compared with individuals with no hepatic steatosis (aHR: 0.42, 95% CI 0.24-0.73). The
227 rest of groups were not associated with all-cause mortality.

228 In subgroup analyses, MAFLD was associated with increased all-cause mortality in female,
229 age >40 years, non-Hispanic white, BMI 18.5-24.9 kg/m², without diabetes and current smoking
230 subgroups (aHR: 1.16-1.57, Figure 2A). For MASLD, similar results were only observed in age
231 41-55 years and non-Hispanic white subgroups. Pure-MASLD was only associated with a higher
232 risk of all-cause mortality in age 41-55 years subgroup. And NAFLD was not associated with all-
233 cause mortality in any subgroups. (Figure 2A)

234 When the analysis was restricted to cause-specific mortality, all the four terms and their
235 combinations were not showed a significant association with cardiovascular mortality or cancer
236 mortality (Table 3). But one combination was excepted, that is, individuals with
237 NAFLD+/MAFLD-/MASLD+/pure-MASLD+ showed both lower risk of cardiovascular mortality
238 and cancer mortality (aHR: 0.17, 95% CI 0.03-0.83; aHR: 0.22, 95% CI 0.07-0.64, respectively).

239 Lastly, we evaluated the effect of fibrosis on the all-cause mortality among NAFLD, MAFLD,
240 MASLD and pure-MASLD. As shown in Table 4, compared to low NFS score group, all the four
241 terms showed increased risk of all-cause mortality irrespective in intermediate NFS score group or
242 high NFS score group, which was larger in high NFS score group (intermediate NFS: aHR: 1.27-

243 1.53; high NFS: aHR: 1.66-1.83, respectively).

244 **Sensitivity analyses of NAFLD, MAFLD, MASLD and pure-MASLD**

245 Firstly, we want to know if other etiologies of SLD will affect the clinical outcomes. After added
246 individuals with other confounders (viral hepatitis and low BMI) to the entire population, similar
247 findings of mortality outcomes were observed (Table S4-7). And then we wonder whether the
248 extent of hepatic steatosis may have an influence on the mortality. After classified into three
249 groups (mild, moderate, and severe) of SLD according to the ultrasound results in NHANES III,
250 we found individuals with moderate and severe SLD were significantly associated with increased
251 all-cause mortality, and had similar effect (aHR: 1.21, 95% CI 1.06-1.39; aHR: 1.22, 95% CI 1.03-
252 1.45, respectively; Table S8). Hence, we conducted another sensitivity analysis excluding the mild
253 hepatic steatosis from SLD (that is, SLD were redefined as those with moderate-severe hepatic
254 steatosis). Notably, in this scenario, not only MAFLD and MASLD were associated with increased
255 all-cause mortality (aHR: 1.25, 95% CI 1.13-1.39; aHR: 1.24, 95% CI 1.12-1.38, respectively),
256 but also NAFLD and pure-MASLD did (aHR: 1.16, 95% CI 1.04-1.30; aHR: 1.18, 95% CI 1.05-
257 1.33, respectively; Table 5). Regarding the different of combinations, the results of
258 NAFLD+/MAFLD+/MASLD+/pure-MASLD+ group and NAFLD-/MAFLD+/MASLD+/pure-
259 MASLD- group were in line with our previous findings (aHR: 1.23, 95% CI 1.10-1.38; aHR: 1.39,
260 95% CI 1.06-1.83, respectively). However, the lower risk of all-cause mortality of
261 NAFLD+/MAFLD-/MASLD+/pure-MASLD+ group in previous was disappeared in this
262 sensitivity analysis, instead of the NAFLD-/MAFLD-/MASLD+/pure-MASLD- group had a
263 higher risk of all-cause mortality (aHR: 2.65, 95% CI 1.70-4.12). (Table 5) Compared to no
264 hepatic steatosis, individuals with MetALD had a higher risk of all-cause mortality (aHR: 1.41,

265 95% CI 1.02-1.94), whereas MASLD with ALD was not associated with all-cause mortality (aHR:
266 1.95, 95% CI 0.97-3.91, P=0.06; Table S9).

267 In addition, for the cause-specific mortality in different terms of SLD, similar results were also
268 observed. Remarkably, we found a powerful protect effect to cardiovascular mortality in
269 NAFLD+/MAFLD-/MASLD-/pure-MASLD- group (aHR: 0.02, 95% CI 0.00-0.18), but it was not
270 occurred in cancer mortality analysis (Table S10). As for the advanced fibrosis, similar results
271 were observed in intermediate and high NFS score groups (Table S11).

272 At last, we also conducted the subgroup analyses in this sensitivity analysis. Interestingly and
273 importantly, all the NALFD, MAFLD, MASLD and pure-MASLD were associated with increased
274 all-cause mortality in female, age 41-55 years, non-Hispanic white and never smoking subgroups
275 (aHR: 1.19-1.61). Moreover, MAFLD and MASLD were associated with higher risk of all-cause
276 mortality in BMI 18.5-24.9 kg/m² and without diabetes subgroups (aHR: 1.18-1.52). (Figure 2B)

277

278 **Discussion**

279 As the new term of MASLD was proposed to replace NAFLD and MAFLD recently, we evaluated
280 the clinical characteristics and mortality outcomes about these different terms in this longitudinal,
281 nationally representative, US population-based study. The main findings of our analysis were: 1)
282 MASLD can identify more individuals with risk of all-cause mortality than MAFLD, due to
283 broader definition of metabolic risk factors; 2) pure-MASLD and NAFLD showed high
284 concordance in their clinical characteristics and outcomes, and both were not associated with all-
285 cause mortality in total SLD individuals; 3) all the NAFLD, MAFLD, MASLD and pure-MASLD
286 were associated with increased all-cause mortality in individuals with advanced fibrosis; 4) a

287 higher risk of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were also
288 observed in female, age 41-55 years, non-Hispanic white, and never smoking subgroups when
289 focused on moderate-severe hepatic steatosis.

290 Regarding to the relatively strict and complex of MAFLD definition ¹⁶, MASLD simplified the
291 number of metabolic risk factors, and relaxed the range of some criteria, such as the waist
292 circumference ². Hence, MASLD will include more SLD individuals than MAFLD in theory, and
293 this was proved by our result, that is, MASLD can identify about 3% more individuals than
294 MAFLD (29.04% vs. 26.13%). This phenomenon was also observed in a previous study from
295 Hong Kong cohort (MASLD: 26.7% vs. MAFLD: 25.9%) ⁵. Although several previous studies
296 had assessed the association between MAFLD and all-cause mortality based on NHAENS III data
297 ^{19 21-23}, the conclusions are still controversial, due to different adjusted models chose. Considering
298 the possible pitfalls in the adjustment model choosing ²⁰, we just adjusted the sociodemographic
299 characteristics and lifestyle risk factors of individuals, and any variable used in their definitions
300 were discarded. In this scenario, our result showed a significant higher risk of all-cause mortality
301 in individuals with MAFLD, which was similar with a recent study using the same strategy ¹¹.

302 Importantly, we found that MASLD was also significantly associated with increased all-cause
303 mortality after adjustment. This result indicated that new term of MASLD is better identify people
304 at risk of all-cause mortality than MAFLD. Because no study focused on the clinical outcome of
305 MASLD in a broad sense before, more studies are needed to verify the result.

306 To better distinguish the effect of alcohol intake from MASLD, the Delphi consensus further
307 classified MASLD into pure-MASLD, MetALD, and MASLD with other etiologies. According to
308 the definition, individuals with excessive alcohol consumption were excluded from both pure-

309 MASLD and NAFLD, but pure-MASLD was restricted by the metabolic risk factors definition ²
310 ¹⁵. In this study, there were 10.1% individuals with NAFLD cannot be classified into pure-
311 MASLD. This was different with previous studies, which showed extremely high (over 99%)
312 accordance between NAFLD and pure-MASLD in cohorts from France ⁶ or Sweden ⁸. This
313 discrepancy may be attributed to the differences of region, race, and enrollment time of
314 participants. As expected, all the individuals with pure-MASLD can be classified into NAFLD.
315 For the mortality outcomes, previous NHANES III based studies showed NAFLD per se was not
316 associated with increased risk of all-cause and cause-specific mortality, which were in line with
317 our result with a more extended follow-up period of the median 27 years ^{19 21 24}. Similarly, we
318 found that pure-MASLD was also not associated with all-cause mortality after adjustment, which
319 was in accordance with a recent study ¹⁰. But Zhao et al. reported a higher risk of all-cause
320 mortality in individuals with pure-MASLD ¹¹. This may due to more participants without alcohol
321 intake information were included in their study, which will result in some people who have no
322 information about alcohol consumption but indeed have excessive alcohol consumption being
323 classified into pure-MASLD group. Our results suggested that NAFLD and pure-MASLD were
324 highly similar in characteristics and clinical outcomes ⁹, hence, old NAFLD data could still be
325 used and new biomarkers to differentiate NAFLD and pure-MASLD may be not needed.
326 Next, we evaluated the mortality among the different combinations of NAFLD, MAFLD, MASLD
327 and pure-MASLD. Due to other confounders of SLD, such as viral hepatitis and low BMI, has
328 been excluded in the main analysis, we can better to focus on the effect of metabolic risk factors
329 and alcohol intake on the outcomes of the four terms. Both NAFLD+/MAFLD+/MASLD+/pure-
330 MASLD+ and NAFLD-/MAFLD+/MASLD+/pure-MASLD- were associated with increased all-

331 cause mortality, and the later showed a larger effect. This indicated that metabolic dysregulation
332 met the criteria of MAFLD alone will increase the mortality risk, and excessive alcohol intake
333 plus metabolic dysregulation will further strengthen the risk of mortality, which was also observed
334 in previous study ¹⁹. Interestingly, we found that NAFLD+/MAFLD-/MASLD+/pure-MASLD+,
335 but not NAFLD+/MAFLD-/MASLD-/pure-MASLD- was associated with lower risk of all-cause
336 and cause-specific mortality. This indicated that instead of no metabolic risk, only slight metabolic
337 risk (MAFLD-/MASLD+) was a protected effect to mortality in individuals with SLD. It is hard
338 for us to explain this odd result now, may be related to the small number of each group, and
339 studies with larger sample size are needed to clarify this. In addition, both NAFLD-/MAFLD-
340 /MASLD+/pure-MASLD- and NAFLD-/MAFLD-/MASLD-/pure-MASLD- were not associated
341 with all-cause and cause-specific mortality. This suggesting that excessive alcohol consumption
342 alone or plus slight metabolic risk will not increase the risk of mortality. Taken together, the
343 increased risk of mortality in SLD was only related to the extent of metabolic dysregulation, and
344 alcohol intake plays a boost role in this.

345 Except for metabolism and alcohol, fibrosis is another factor related to poor progress ²⁵. Here, we
346 used the NFS score, as a surrogate index due to lack of the liver biopsy, to assess the possibility of
347 advanced fibrosis ¹⁷. Previous study showed that advanced fibrosis in MAFLD, but not NAFLD,
348 was associated with a higher risk of all-cause mortality ¹⁹. In our analysis, not only MAFLD, but
349 also NAFLD, MASLD and pure-MASLD were associated with increased all-cause mortality, and
350 the effects were larger with higher NFS score. Hence, even in the new term of MASLD,
351 individuals with advanced fibrosis are still a special population needed to pay more attention.

352 In subgroup analyses, we noticed that both MAFLD and MASLD were associated with increased

353 all-cause mortality in middle age (41-55 years) and non-Hispanic white subgroups. And both
354 NAFLD and pure-MASLD were not associated with all-cause mortality in any subgroup, which
355 was similar with a previous study on NAFLD ²⁴. Notably, more powerful effects of all-cause-
356 mortality risk were observed among the four terms after excluding individuals with mild hepatic
357 steatosis from those with SLD. In this sensitivity analysis, individuals with NAFLD, MAFLD,
358 MASLD and pure-MASLD had higher risk of all-cause-mortality in female, middle age, non-
359 Hispanic white and never smoking subgroups. The reasons for these phenomena are complex and
360 unclear. For the age, we speculated the reason may be that the younger subgroup had a lower
361 mortality and the older subgroup had a higher mortality, which may counteract the effects of
362 NAFLD, MAFLD, MASLD and pure-MASLD. Similarly, we guessed that individuals with the
363 history of smoking (irrespective of previous or current smoking) had a higher mortality than never
364 smoking subgroup ²⁶, which may weaken the discrepancy caused by NAFLD, MAFLD, MASLD
365 and pure-MASLD. But for sex and race, it is hard to confirm the specific cause now. The results in
366 subgroup analyses needed more studies to investigate and verify in future. All in all, subgroup and
367 sensitivity analyses showed the increased all-cause mortality among NAFLD, MAFLD, MASLD
368 and pure-MASLD were related to sex, age, race, smoking status and the extent of hepatic
369 steatosis.

370 Our study has some strengths. First, we comprehensively compared the clinical characteristics and
371 outcomes of NAFLD, MAFLD, MASLD and pure-MASLD using the NHANES III data, a large
372 nationally representative sample of the US population with a long follow-up period for mortality
373 (median of 27 years). Second, we conducted a strict screen strategy excluding individuals without
374 alcohol consumption information, or with other confounders (such as pregnancy, abnormal liver

375 enzymes levels, viral hepatitis, or BMI less than 18.5 kg/m²), so that we can focus on the effect of
376 metabolic risk factors and alcohol intake on the mortality of these terms. Third, we first found that
377 the increased all-cause mortality among NAFLD, MAFLD, MASLD and pure-MASLD were
378 associated with sex, age, race, smoking status and the extent of hepatic steatosis in subgroup and
379 sensitivity analyses. Although the specific cause is unclear, more attention and earlier intervention
380 should be paid to these special populations in future.

381 Meanwhile, our study also has some limitations. First, due to the participants in NHANES III were
382 included between 1988-1994, the prevalence of NAFLD, MAFLD, MASLD and pure-MASLD
383 may not reflect the current extent. Second, due to the cross-sectional design of NHANES, we were
384 unable to assess dynamic changes in NAFLD, MAFLD, MASLD and pure-MASLD status over
385 time. Third, individuals with viral hepatitis or low BMI were added into the entire population in
386 sensitivity analysis, and similar results were observed. But considering the number of these
387 individuals were relatively small, the results should be interpreted with caution. Hence, the
388 specific effect of viral hepatitis on the mortality outcomes in SLD is still need to be verified in
389 studies with larger samples, especially in Asia and Africa where the prevalence of viral hepatitis
390 was high²⁷. Despite some of these limitations, we believe our findings are still important and
391 meaningful, benefited of a large population-based study using a nationally representative sample
392 and sufficient follow-up period.

393 In conclusion, the definition of MASLD was better than MAFLD to identify more individuals
394 with poor progress, whereas, pure-MASLD had similar characteristics and mortality outcomes
395 with NAFLD. The increased all-cause mortality of SLD was only associated with the extent of
396 metabolic dysfunction, but excessive alcohol intake will enlarge this effect. Moreover, higher risk

397 of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were also observed in
398 individuals with advanced fibrosis and moderate-severe of hepatic steatosis, and in female, middle
399 age, non-Hispanic white, and never smoking subgroups. Well-designed prospective studies with
400 larger samples are needed to verify our observations in future.

401 **Acknowledgement**

402 We gratefully acknowledge the contribution of the participants of the NHANES cohort, research
403 assistants, and facilitating personnel. And this work was supported by the first batch of key
404 disciplines on public health in Chongqing, Health Commission of Chongqing, China.

405 **Conflict of interest**

406 The authors declare no conflicts of interest.

407 **Author contributions**

408 Rui Song, Zhao Li and Yingzhi Zhang was involved in acquisition of data, data analysis and
409 interpretation, drafting of the manuscript, and study supervision. Jiahe Tan were involved in
410 interpretation of data and critical revision of the manuscript. Zhiwei Chen was involved in study
411 concept and design, interpretation of data, drafting of the manuscript, critical revision of the
412 manuscript, and study supervision. All authors contributed to the article and approved the
413 submitted version.

414 **References**

- 415 1. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden,
416 Adverse Outcomes and Associations. *J Clin Transl Hepatol* 2020;8(1):76-86.
- 417 2. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new
418 fatty liver disease nomenclature. *J Hepatol* 2023;S0168-8278(23)00418-X.


- 419 3. Sanal MG. NAFLD to MASLD is wokeism? *J Hepatol* 2023;S0168-8278(23)05081-X.
- 420 4. Emanuele E, Minoretta P. Letter to the Editor: NAFLD, MAFLD or MASLD? cut the Gordian
421 knot with "Ludwig disease". *Hepatology* 2023.
- 422 5. Song SJ, Che-To Lai J, Lai-Hung Wong G, et al. Can we use old NAFLD data under the new
423 MASLD definition? *J Hepatol* 2023;S0168-8278(23)05000-6.
- 424 6. Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed when
425 transitioning from NAFLD to MASLD. *J Hepatol* 2023;S0168-8278(23)04996-6.
- 426 7. Chen L, Tao X, Zeng M, et al. Clinical and histological features under different nomenclatures
427 of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. *J Hepatol* 2023;S0168-
428 8278(23)05075-4.
- 429 8. Hagström H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria
430 and natural history is therefore identical. *J Hepatol* 2023;S0168-8278(23)05080-8.
- 431 9. Perazzo H, Pacheco AG, Griep RH. Changing from NAFLD through MAFLD to MASLD:
432 similar prevalence and risk factors in a large Brazilian cohort. *J Hepatol* 2023;S0168-
433 8278(23)05079-1.
- 434 10. Li M, Xie W. Are there all-cause mortality differences between metabolic dysfunction-
435 associated steatotic liver disease subtypes? *J Hepatol* 2023;S0168-8278(23)04989-9.
- 436 11. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or
437 MAFLD. *J Hepatol* 2023;S0168-8278(23)05055-9.
- 438 12. Chen VL, Song MW, Suresh D, et al. Effects of social determinants of health on mortality and
439 incident liver-related events and cardiovascular disease in steatotic liver disease. *Aliment
440 Pharmacol Ther* 2023;58(5):537-45.


- 441 13. National Center for Health Statistics CfDCaP. Analytic and reporting guidelines: The Third
442 National Health and Nutrition Examination Survey, NHANES III (1988-94) 1996 [Available from:
443 [https://www.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-](https://www.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf)
444 [guidelines.pdf](https://www.cdc.gov/nchs/data/nhanes/analyticguidelines/88-94-analytic-reporting-guidelines.pdf) (Access on 2023.09.19).
- 445 14. III NHaNESN. Hepatic Steatosis Ultrasound Images Assessment Procedures Manual 2010
446 [Available from:
447 [https://www.cdc.gov/nchs/data/nhanes/nhanes3/hepatic_steatosis_ultrasound_procedures_manual.](https://www.cdc.gov/nchs/data/nhanes/nhanes3/hepatic_steatosis_ultrasound_procedures_manual.pdf)
448 [pdf](https://www.cdc.gov/nchs/data/nhanes/nhanes3/hepatic_steatosis_ultrasound_procedures_manual.pdf) (Asscess on 2023.09.19).
- 449 15. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet
450 2021;397(10290):2212-24.
- 451 16. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-
452 associated fatty liver disease: An international expert consensus statement. J Hepatol
453 2020;73(1):202-09.
- 454 17. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that
455 identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45(4):846-54.
- 456 18. Statistics NCfH. 2019 Public-Use Linked Mortality Files 2022 [Available from:
457 <https://www.cdc.gov/nchs/data-linkage/mortality-public.htm> (Access on 2023.09.19).
- 458 19. Kim D, Konyon P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is
459 associated with increased all-cause mortality in the United States. J Hepatol 2021;75(6):1284-91.
- 460 20. Attia D, Gomaa A, Abdel Alem S. Letter to the editor: Pitfalls in the outcome differences
461 between NAFLD and MAFLD. Hepatology 2022;76(5):E100.
- 462 21. Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD

- 463 and metabolic-associated fatty liver disease? *Hepatology* 2022;76(5):1423-37.
- 464 22. van Kleef LA, de Knecht RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease
465 and excessive alcohol consumption are both independent risk factors for mortality. *Hepatology*
466 2023;77(3):942-48.
- 467 23. Huang Q, Zou X, Wen X, et al. NAFLD or MAFLD: Which Has Closer Association With All-
468 Cause and Cause-Specific Mortality?-Results From NHANES III. *Front Med (Lausanne)*
469 2021;8:693507.
- 470 24. Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among
471 US adults: prospective cohort study. *Bmj* 2011;343:d6891.
- 472 25. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A
473 Review. *Jama* 2023;329(18):1589-602.
- 474 26. Cunha ARD, Compton K, Xu R, et al. The Global, Regional, and National Burden of Adult
475 Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the
476 Global Burden of Disease Study 2019. *JAMA Oncol* 2023;e232960.
- 477 27. Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. *J*
478 *Hepatol* 2023;79(2):516-37.
- 479
- 480
- 481
- 482
- 483
- 484

485 **Figure and Figure Legends**

486





498

499 **Figure 2. Subgroup analyses of association with all-cause mortality among NAFLD,**

500 **MAFLD, MASLD and pure-MASLD in total SLD individuals (A) and in moderate-severe**

501 **SLD individuals (B). Green box means HR value without statistical difference. Red box means**

502 **HR value with statistical difference. The bars on both sides of box mean 95% CI of HR. The**

503 **adjusted model 2 (sex, age, race/ethnicity, marital status, education, sedentary lifestyle, and**

504 **smoking status) was used in this analysis. BMI, body mass index; CI, confidence intervals. HR,**

505 hazard ratio; SLD, steatotic liver disease; MAFLD, dysfunction-associated fatty liver disease;

506 MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty

507 liver disease metabolic.

508

509

510

511

512

513

514

515

516

517

Table 1. Baseline characteristics of the study population (N = 6,708).

Characteristics	No hepatic steatosis (n=4,544)	Group 1# (n=1,575)	Group 2# (n=178)	Group 3# (n=166)	Group 4# (n=196)	Group 5# (n=29)	Group 6# (n=20)	P
Age (years)	36.0 (28.0, 48.0)	47.0 (36.0, 60.0)	47.0 (35.0, 58.9)	32.0 (26.0, 44.0)	30.0 (25.0, 39.0)	37.0 (29.3, 62.0)	30.0 (27.2, 31.5)	<0.001
Sex (male)	2,301 (52%)	773 (56%)	135 (76%)	57 (30%)	86 (41%)	23 (76%)	15 (69%)	<0.001
Race/ethnicity								0.10
Non-Hispanic white	1,814 (78%)	597 (75%)	76 (86%)	75 (83%)	80 (82%)	12 (81%)	9 (83%)	
Non-Hispanic black	1,198 (4.5%)	560 (6.3%)	62 (5.1%)	43 (3.5%)	50 (4.7%)	8 (5.3%)	2 (1.2%)	
Mexican-American	1,324 (9.8%)	348 (8.2%)	36 (6.3%)	40 (7.8%)	61 (8.4%)	9 (13%)	8 (8.7%)	
Others	208 (8.1%)	70 (10%)	4 (2.9%)	8 (5.9%)	5 (4.4%)	0 (0%)	1 (7.0%)	
Body mass index (kg/m ²)	24.6 (22.3, 27.3)	29.3 (26.5, 32.4)	28.3 (25.9, 32.2)	22.0 (20.9, 23.7)	21.7 (20.4, 22.9)	22.7 (20.6, 24.1)	21.2 (19.7, 21.9)	<0.001
Waist circumference (cm)	88 (79, 96)	102 (94, 110)	100 (91, 110)	81 (73, 85)	74 (70, 79)	84 (81, 91)	75 (70, 79)	<0.001
≥12 years education	3,094 (82%)	874 (73%)	106 (78%)	111 (82%)	138 (81%)	18 (86%)	12 (61%)	<0.001
Marital status	2,798 (65%)	1,097 (75%)	117 (64%)	101 (62%)	117 (73%)	17 (81%)	10 (63%)	<0.001
Hypertension	1,140 (20%)	691 (43%)	105 (67%)	22 (8.9%)	5 (2.7%)	9 (28%)	2 (10%)	<0.001
Diabetes	219 (2.8%)	298 (13%)	25 (9.1%)	1 (0.8%)	0 (0%)	0 (0%)	0 (0%)	<0.001
Smoking status								<0.001
Never	2,297 (46%)	826 (48%)	41 (30%)	91 (49%)	111 (57%)	6 (11%)	5 (15%)	
Past smoker	866 (22%)	427 (30%)	64 (37%)	24 (15%)	22 (14%)	6 (23%)	2 (16%)	
Current smoker	1,381 (32%)	322 (22%)	73 (33%)	51 (36%)	63 (29%)	17 (66%)	13 (68%)	
Alcohol consumption (g/d)	4 (1, 12)	2 (0, 8)	42 (36, 60)	3 (1, 6)	4 (1, 12)	48 (32, 56)	61 (36, 82)	<0.001
Sedentary lifestyle	1,061 (16%)	520 (24%)	42 (16%)	41 (17%)	37 (9.5%)	9 (28%)	6 (42%)	<0.001
Triglycerides (mg/dL)	1.1 (0.8, 1.6)	1.8 (1.2, 2.6)	1.6 (1.2, 2.3)	1.0 (0.8, 1.3)	0.9 (0.7, 1.2)	0.8 (0.7, 1.1)	0.7 (0.5, 1.1)	<0.001
HDL-cholesterol (mg/dL)	1.3 (1.1, 1.6)	1.1 (0.9, 1.3)	1.3 (1.0, 1.5)	1.3 (1.1, 1.5)	1.6 (1.3, 1.8)	1.5 (1.3, 1.8)	1.9 (1.3, 2.3)	<0.001

C-reactive protein (mg/dL)	0.2 (0.2, 0.2)	0.2 (0.2, 0.5)	0.2 (0.2, 0.4)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	<0.001
Glucose (mol/L)	5.1 (4.8, 5.4)	5.4 (5.0, 5.8)	5.3 (4.9, 5.6)	5.0 (4.7, 5.3)	4.9 (4.7, 5.2)	5.2 (4.9, 5.5)	5.0 (4.5, 5.6)	<0.001
Insulin (uU/mL)	7.0 (5.4, 9.7)	11.4 (8.3, 15.9)	9.6 (7.1, 13.6)	7.1 (5.1, 8.5)	5.6 (4.7, 7.4)	5.3 (4.1, 6.9)	4.2 (4.2, 5.4)	<0.001
Hemoglobin A1c (%)	5.1 (4.8, 5.4)	5.4 (5.0, 5.7)	5.2 (5.0, 5.5)	5.1 (4.8, 5.3)	5.0 (4.6, 5.3)	5.0 (4.5, 5.3)	5.1 (4.7, 5.1)	<0.001
HOMA-IR	1.6 (1.2, 2.3)	2.8 (2.0, 4.2)	2.2 (1.6, 3.3)	1.5 (1.1, 1.9)	1.2 (1.0, 1.7)	1.2 (1.0, 1.5)	1.1 (0.9, 1.3)	<0.001

Data are shown as the median (interquartile range) or unweighted frequency counts (weighted percentage) as appropriate. The Kruskal-Wallis test for continuous variables and the Chi-square test for categorical variables were used in this analysis.

Group 1, NAFLD+/MAFLD+/MASLD+/pure-MASLD+; Group 2, NAFLD+/MAFLD-/MASLD+/pure-MASLD+; Group 3, NAFLD-/MAFLD+/MASLD+/pure-MASLD-; Group 4, NAFLD+/MAFLD-/MASLD-/pure-MASLD-; Group 5, NAFLD-/MAFLD-/MASLD+/pure-MASLD-; Group 6, NAFLD-/MAFLD-/MASLD-/pure-MASLD-.

HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

Table 2. Association among NAFLD, MAFLD, MASLD and pure-MASLD status, and all-cause mortality.

				N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
						HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
No SLD				4,544	1,244	1		1		1	
SLD				2,164	817	1.61 (1.43-1.80)	<0.001	1.13 (1.01-1.27)	0.039	1.12 (1.00-1.25)	0.046
No NAFLD				4,771	1,348	1		1		1	
NAFLD				1,937	713	1.5 (1.32-1.70)	<0.001	1.07 (0.95-1.20)	0.3	1.07 (0.95-1.20)	0.2
No MAFLD				4,958	1309	1		1		1	
MAFLD				1,753	752	2.1 (1.86-2.36)	<0.001	1.19 (1.07-1.34)	0.002	1.21 (1.09-1.35)	<0.001
No MASLD				4,760	1,269	1		1		1	
MASLD				1,948	792	1.85 (1.67-2.05)	<0.001	1.13 (1.01-1.26)	0.032	1.11 (1.00-1.23)	0.048
No pure-MASLD				4,967	1,368	1		1		1	
Pure-MASLD				1,741	693	1.72 (1.51-1.96)	<0.001	1.07 (0.96-1.20)	0.2	1.07 (0.96-1.19)	0.3
No hepatic steatosis				4,544	1,244	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,575	665	1.97 (1.73-2.25)	<0.001	1.15 (1.03-1.29)	0.017	1.17 (1.05-1.30)	0.006
-	+	+	-	178	87	2.25 (1.56-3.25)	<0.001	1.42 (1.03-1.96)	0.035	1.34 (1.02-1.77)	0.036
+	-	+	+	166	28	0.45 (0.27-0.77)	0.003	0.52 (0.34-0.80)	0.003	0.42 (0.24-0.73)	0.002
+	-	-	-	196	20	0.49 (0.27-0.89)	0.02	1.03 (0.65-1.64)	>0.9	1.13 (0.72-1.77)	0.6
-	-	+	-	29	12	1.99 (0.81-4.90)	0.13	1.33 (0.61-2.93)	0.5	1.01 (0.35-2.89)	>0.9
-	-	-	-	20	5	0.65 (0.16-2.74)	0.6	2.41 (0.68-8.56)	0.2	1.61 (0.45-5.78)	0.5

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; SLD, steatosis liver disease; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

Table 3. Association among NAFLD, MAFLD, MASLD and pure-MASLD status, and cardiovascular disease and cancer-related mortality.

				N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
						HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Cardiovascular mortality											
No NAFLD				4,771	347	1		1		1	
NAFLD				1,937	190	1.43 (1.07-1.93)	0.017	0.97 (0.73-1.29)	0.8	0.96 (0.71-1.30)	0.8
No MAFLD				4,958	332	1		1		1	
MAFLD				1,753	205	2.23 (1.71-2.91)	<0.001	1.19 (0.92-1.53)	0.2	1.21 (0.94-1.57)	0.14
No MASLD				4,760	324	1		1		1	
MASLD				1,948	213	1.90 (1.44-2.49)	<0.001	1.08 (0.83-1.42)	0.5	1.06 (0.81-1.40)	0.7
No pure-MASLD				4,967	350	1		1		1	
Pure-MASLD				1,741	187	1.74 (1.31-2.30)	<0.001	1.01 (0.76-1.35)	>0.9	1.00 (0.74-1.36)	>0.9
No hepatic steatosis				4,544	319	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,575	182	2.02 (1.52-2.67)	<0.001	1.1 (0.83- 1.46)	0.5	1.12 (0.84, 1.48)	0.4
-	+	+	-	178	23	2.53 (1.37-4.67)	0.003	1.55 (0.79- 3.04)	0.2	1.47 (0.79, 2.74)	0.2
+	-	+	+	166	5	0.20 (0.04-0.96)	0.015	0.23 (0.05- 1.07)	0.06	0.17 (0.03, 0.83)	0.029
+	-	-	-	196	3	0.11 (0.02-0.67)	0.016	0.27 (0.04- 1.70)	0.2	0.31 (0.06, 1.69)	0.2
-	-	+	-	29	3	1.20 (0.27-5.34)	0.8	0.71 (0.14- 3.71)	0.7	0.63 (0.13, 3.11)	0.6
-	-	-	-	20	2	1.53 (0.22-10.80)	0.7	8 (1.44- 44.4)	0.017	4.99 (0.88, 28.2)	0.069
Cancer mortality											
No NAFLD				4,771	358	1		1		1	
NAFLD				1,937	165	1.27 (0.93, 1.74)	0.14	0.94 (0.69, 1.29)	0.7	0.99 (0.72, 1.36)	>0.9
No MAFLD				4,958	348	1		1		1	
MAFLD				1,753	175	1.89 (1.46, 2.45)	<0.001	1.13 (0.86, 1.48)	0.4	1.21 (0.92, 1.60)	0.2
No MASLD				4,760	337	1		1		1	

MASLD				1,948	186	1.63 (1.29, 2.07)	<0.001	1.04 (0.80, 1.35)	0.8	1.07 (0.83, 1.39)	0.6
No pure-MASLD				4,967	363	1		1		1	
Pure-MASLD				1,741	160	1.44 (1.07, 1.94)	0.016	0.94 (0.70, 1.27)	0.7	0.98 (0.73, 1.33)	>0.9
No hepatic steatosis				4,544	331	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,575	152	1.69 (1.24- 2.32)	0.001	1.04 (0.76- 1.41)	0.8	1.11 (0.81- 1.52)	0.5
-	+	+	-	178	23	2.59 (1.44- 4.67)	0.001	1.63 (0.92- 2.87)	0.092	1.61 (0.93- 2.78)	0.09
+	-	+	+	166	8	0.26 (0.10- 0.64)	0.004	0.3 (0.12- 0.77)	0.012	0.22 (0.07- 0.64)	0.006
+	-	-	-	196	5	0.52 (0.15- 1.75)	0.3	0.99 (0.30- 3.26)	>0.9	1.07 (0.31- 3.66)	>0.9
-	-	+	-	29	3	1.69 (0.39- 7.27)	0.5	1.19 (0.23- 6.09)	0.8	0.8 (0.14- 4.47)	0.8
-	-	-	-	20	1	0.74 (0.09- 6.32)	0.8	1.87 (0.23- 15.1)	0.6	1.21 (0.14- 10.2)	0.9

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.

Table 4. Association of advanced fibrosis status and all-cause mortality among individuals with NAFLD, MAFLD, MASLD and pure-MASLD.

	N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
			HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
NAFLD								
Low NFS	1,277	294	1		1		1	
Intermediate NFS	545	331	4.07 (3.18, 5.21)	<0.001	1.24 (1.00, 1.53)	0.048	1.27 (1.04, 1.55)	0.02
High NFS	97	79	6.98 (4.44, 11.0)	<0.001	1.87 (1.25, 2.80)	0.002	1.79 (1.24, 2.60)	0.002
MAFLD								
Low NFS	1,064	299	1		1		1	
Intermediate NFS	570	359	3.74 (2.90, 4.81)	<0.001	1.45 (1.16, 1.80)	0.001	1.53 (1.24, 1.89)	<0.001
High NFS	103	85	6.35 (4.16, 9.68)	<0.001	1.93 (1.32, 2.81)	<0.001	1.83 (1.29, 2.59)	<0.001
MASLD								
Low NFS	1,227	323	1		1		1	
Intermediate NFS	595	373	3.9 (3.04, 5.00)	<0.001	1.38 (1.12, 1.70)	0.003	1.41 (1.15, 1.72)	<0.001
High NFS	106	86	6.34 (4.15, 9.69)	<0.001	1.81 (1.25, 2.63)	0.002	1.66 (1.14, 2.42)	0.008
Pure-MASLD								
Low NFS	1,097	280	1		1		1	
Intermediate NFS	532	327	3.79 (3.00, 4.81)	<0.001	1.28 (1.03, 1.58)	0.027	1.31 (1.06, 1.62)	0.011
High NFS	95	78	6.73 (4.28, 10.6)	<0.001	1.88 (1.22, 2.91)	0.005	1.8 (1.20, 2.69)	0.004

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic; NFS, NAFLD fibrosis score.

Table 5. Association among NAFLD, MAFLD, MASLD and pure-MASLD status, and all-cause mortality in individuals with moderate-severe hepatic steatosis[#].

				N	n (deaths)	Univariable model		Multivariable Model 1		Multivariable Model 2	
						HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
No NAFLD				4,682	1,319	1		1		1	
NAFLD				1,155	491	1.96 (1.70, 2.26)	<0.001	1.15 (1.04, 1.28)	0.006	1.16 (1.04, 1.30)	0.01
No MAFLD				4,700	1,281	1		1		1	
MAFLD				1,137	529	2.39 (2.14, 2.68)	<0.001	1.25 (1.12, 1.39)	<0.001	1.25 (1.13, 1.39)	<0.001
No MASLD				4,614	1,251	1		1		1	
MASLD				1,223	559	2.26 (2.01, 2.55)	<0.001	1.25 (1.13, 1.39)	<0.001	1.24 (1.12, 1.38)	<0.001
No pure-MASLD				4,745	1324	1		1		1	
Pure-MASLD				1,092	486	2.08 (1.81, 2.40)	<0.001	1.18 (1.06, 1.31)	0.003	1.18 (1.05, 1.33)	0.005
No hepatic steatosis				4,544	1,244	1		1		1	
NAFLD	MAFLD	MASLD	pure-MASLD								
+	+	+	+	1,022	466	2.31 (2.04, 2.63)	<0.001	1.22 (1.10, 1.36)	<0.001	1.23 (1.10, 1.38)	<0.001
-	+	+	-	115	63	2.89 (1.88, 4.46)	<0.001	1.49 (1.07, 2.07)	0.018	1.39 (1.06, 1.83)	0.019
+	-	+	+	70	20	0.77 (0.35, 1.67)	0.5	0.89 (0.60, 1.31)	0.5	0.8 (0.44, 1.42)	0.4
+	-	-	-	63	5	0.29 (0.09, 0.97)	0.045	0.43 (0.15, 1.24)	0.12	0.48 (0.21, 1.10)	0.083
-	-	+	-	16	10	3.97 (1.66, 9.51)	0.002	2.56 (1.28, 5.11)	0.008	2.65 (1.70, 4.12)	<0.001
-	-	-	-	7	2	0.66 (0.08, 5.38)	0.7	2.03 (0.32, 12.9)	0.5	1.26 (0.20, 8.02)	0.8

[#] (n=5,837) excluding individuals with mild hepatic steatosis from the SLD.

Survey-weight adjusted multivariable Cox proportional models were used in this analysis.

Multivariate model 1 was adjusted for sex, age, and race/ethnicity.

Multivariate model 2 was further adjusted for marital status, education, sedentary lifestyle, and smoking status in addition to model 1.

CI, confidential intervals; HR, hazard ratio; SLD, steatosis liver disease; MAFLD, dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; NAFLD, non-alcoholic fatty liver disease metabolic.